Rhizen Pharmaceuticals gets USFDA approval for phase one clinical trials for Covid-19 drug

The Switzerland-based firm, which is a clinical-stage oncology-focussed biopharmaceutical company, has received approval for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to study its oral Dihydroorotate dehydrogenase (DHOHD) inhibitor for SARS-CoV-2 infection, Rhizen Pharmaceuticals S A said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Vss8yQ
via IFTTT